Adial Pharmaceuticals regains Nasdaq equity compliance after $3.6M offering

ADIAL PHARMACEUTICALS, INC.

Received Nasdaq deficiency notice on May 23, 2025 for stockholders' equity of $2,126,662, below $2.5M minimum.
Completed June 18, 2025 offering raising ~$3.6M gross via shares and warrants at $0.3251 per unit.
Company believes it has now regained compliance with Nasdaq stockholders' equity requirement.
Nasdaq will continue to monitor compliance; further non-compliance could lead to delisting.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.